105 reports of this reaction
2.2% of all MECLIZINE HCL reports
#9 most reported adverse reaction
ASTHENIA is the #9 most commonly reported adverse reaction for MECLIZINE HCL, manufactured by Rising Pharma Holdings, Inc.. There are 105 FDA adverse event reports linking MECLIZINE HCL to ASTHENIA. This represents approximately 2.2% of all 4,811 adverse event reports for this drug.
Patients taking MECLIZINE HCL who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for MECLIZINE HCL, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for MECLIZINE HCL:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 105 FDA reports for MECLIZINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 2.2% of all adverse event reports for MECLIZINE HCL, making it a notable side effect.
If you experience asthenia while taking MECLIZINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.